Brokerage firm Bank of America Downgrades its rating on Theravance Biopharma Inc(NASDAQ:TBPH). The shares have been rated Underperform. Previously, the analysts had a Neutral rating on the shares. The rating by Bank of America was issued on Aug 3, 2016.
In a different note, Guggenheim Securities said it Initiates Coverage on Theravance Biopharma Inc, according to a research note issued on Jun 20, 2016. The shares have been rated ‘Buy’ by the firm.
Theravance Biopharma Inc (TBPH) made into the market gainers list on Fridays trading session with the shares advancing 3.85% or 1 points. Due to strong positive momentum, the stock ended at $26.96, which is also near the day’s high of $27. The stock began the session at $25.97 and the volume stood at 3,61,252 shares. The 52-week high of the shares is $27.5899 and the 52 week low is $10.56. The company has a current market capitalization of $1,290 M and it has 4,78,51,848 shares in outstanding.
Theravance Biopharma Inc(TBPH) last announced its earnings results on May 9, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $18.41M. Analysts had an estimated revenue of $18.69M. Earnings per share were $-1.10. Analysts had estimated an EPS of $-1.03.
Several Insider Transactions has been reported to the SEC. On Mar 15, 2016, Plc Glaxosmithkline (10% owner) purchased 1,301,015 shares at $17.70 per share price.Also, On Aug 18, 2015, Junning Lee (Sr. VP, Technical Operations) purchased 9,000 shares at $12.90 per share price.On Aug 18, 2015, Burton G Malkiel (director) purchased 10,000 shares at $12.92 per share price, according to the Form-4 filing with the securities and exchange commission.
Theravance Biopharma Inc. (Theravance Biopharma) is a biopharmaceutical company. The Company is engaged to create value from a diverse set of assets: an approved product; a development pipeline of mid- and late-stage assets and a productive research platform designed for long-term growth. VIBATIV (telavancin) its commercial product is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. TD-4208 is an investigational long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily nebulized treatment for chronic obstructive pulmonary disease (COPD). Axelopran (TD-1211) is an investigational potential once-daily oral treatment for opioid-induced constipation (OIC). Its earlier-stage clinical assets represent approaches for potentially treating diseases of the lung and gastrointestinal tract and infectious disease.